Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases.
about
Manganese neurotoxicity and the role of reactive oxygen speciesMitochondrial dysfunction: different routes to Alzheimer's disease therapyTargeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesisFirst-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergeticsCell Permeable Peptides: A Promising Tool to Deliver Neuroprotective Agents in the Brain.Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive declineThe mitochondrial pathway of anesthetic isoflurane-induced apoptosis.Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities.Mitochondrial oxidative stress and mammalian healthspan.Potential therapeutic benefits of strategies directed to mitochondria.Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection.Toxicity of neurons treated with herbicides and neuroprotection by mitochondria-targeted antioxidant SS31.Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer's diseaseMitochondrial Dysfunction and Oxidative Stress in Asthma: Implications for Mitochondria-Targeted Antioxidant TherapeuticsMitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons.Mitochondrial approaches to protect against cardiac ischemia and reperfusion injury.The endoplasmic reticulum-resident chaperone heat shock protein 47 protects the Golgi apparatus from the effects of O-glycosylation inhibition.Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeuticsMitochondria as a therapeutic target for aging and neurodegenerative diseases.Cardiac aging: from molecular mechanisms to significance in human health and diseaseIs amyloid binding alcohol dehydrogenase a drug target for treating Alzheimer's disease?Mitochondrial dysfunction and neurodegeneration in multiple sclerosisMitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease.Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones.The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?Role of mitochondrial dysfunction and altered autophagy in cardiovascular aging and disease: from mechanisms to therapeutics.Mitochondrial protein tyrosine nitration.Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development.Polyphenols and human health: a prospectus.The role of autophagy in Parkinson's disease.The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease.Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants.A Powerful Mitochondria-Targeted Iron Chelator Affords High Photoprotection against Solar Ultraviolet A Radiation.Alzheimer's Disease: From Mitochondrial Perturbations to Mitochondrial Medicine.Mitochondria as a target for neuroprotection: implications for Alzheimer´s disease.Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications.Targeted overexpression of mitochondrial catalase protects against cancer chemotherapy-induced skeletal muscle dysfunction.In vivo high-resolution magic angle spinning magnetic and electron paramagnetic resonance spectroscopic analysis of mitochondria-targeted peptide in Drosophila melanogaster with trauma-induced thoracic injury.
P2860
Q26853665-BFA06CA9-016C-456C-94CF-E115BE177C8CQ27009475-3FE9DF1E-651E-447F-BD7B-9A770302DB9FQ28383442-DC2FAD9D-E636-4B79-9C0D-2C881E8DB490Q28383451-72832BC1-F611-45AA-8D1E-862CD1002B05Q30437957-DCA84AC4-42BC-47F6-9C3B-995A32D9BD32Q30476347-A6230C77-FDAA-4B68-A511-1A17180C4292Q33662266-6FA7D1E0-3237-4A65-A696-AE7D227D725AQ33668501-266E2CF2-7B74-4D01-8659-E60E6028F08DQ34104004-C744E4A0-00ED-4C10-BC2F-83A97F549A5CQ34117168-2DE9859B-5C7C-40CB-A64B-CA006CA6DC87Q34460675-D7231DDD-5094-4CF6-9C89-18BBB3688C2AQ34566188-BE7758DE-96E4-4502-A24B-E9ACB6333407Q34667337-74E25A43-8C33-4084-B33C-029FBACD6EBAQ34731547-3DCDE491-7AE6-4AB9-95B0-58418AA1356DQ34772619-8623B141-36B2-46F0-899F-B34AE46D60E3Q34854255-E2A07E9C-13DE-4699-AE7D-C99547BFC035Q34903670-9DB66700-3FF1-4C20-8474-EA9553978EA5Q35737647-A262D9B2-99A1-4FA5-B3E9-05B1C5725A88Q35807409-BC8BDA72-41A1-471B-A5A2-E809758D9150Q35898648-17CAE5A4-A5AC-4479-AD0B-494E6172B53AQ36908481-58129EEA-1A98-4860-A028-08BFA1928D2CQ37044232-0119FB87-E025-4D25-B6CD-382C553C6AE4Q37178581-5F0E7DA3-CBD1-4305-8EC6-84C5D71E9901Q37396817-759AA302-1F0B-45F6-9A27-5F2235B9F56BQ37441183-6ADC62D7-B692-40BE-8EFA-093D4455A168Q37476530-D52B9710-265D-4A76-B825-C9FD3AC58FD0Q37799814-8F798F28-689D-4B59-BB56-A10C46631F30Q37884459-DA521241-7C86-413E-9C47-4F4D1CC9CDCFQ37934984-712282DC-00F0-4B74-928E-7305561A5F8AQ37999796-509ED132-8817-463E-BCCC-58616B317026Q38202314-FB3B029A-E38D-433B-B4D3-72579F87C15DQ38253060-ACCF4221-CD5C-4BC6-8482-2BB956662BDBQ38775707-66408D46-7DC0-4C42-B723-C029B7E6E91AQ38872085-71718611-19F1-4C64-A647-4B67F3DF823CQ38883083-7C06FD7F-E4B7-41CD-A96E-1D3D497825BEQ39400621-6FA620AE-AF53-4B85-9DD7-23699BAD0000Q40982094-26EC5164-1F2B-4B82-8995-FE253E658558Q43083626-F590C14B-6381-4E08-91C4-A7B0E5F9E646
P2860
Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Development of mitochondria-ta ...... or neurodegenerative diseases.
@ast
Development of mitochondria-ta ...... or neurodegenerative diseases.
@en
Development of mitochondria-ta ...... or neurodegenerative diseases.
@nl
type
label
Development of mitochondria-ta ...... or neurodegenerative diseases.
@ast
Development of mitochondria-ta ...... or neurodegenerative diseases.
@en
Development of mitochondria-ta ...... or neurodegenerative diseases.
@nl
prefLabel
Development of mitochondria-ta ...... or neurodegenerative diseases.
@ast
Development of mitochondria-ta ...... or neurodegenerative diseases.
@en
Development of mitochondria-ta ...... or neurodegenerative diseases.
@nl
P356
P1476
Development of mitochondria-ta ...... or neurodegenerative diseases.
@en
P2093
Hazel H Szeto
P2860
P304
P356
10.1196/ANNALS.1427.013
P407
P577
2008-12-01T00:00:00Z